Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Transplant Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease (cGVHD)
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

NCT00178425
View directory record Official record
Conditions
Transplantation, Liver
Interventions
Serial blood sampling as described in protocol, Estimation of Creatinine Clearance at regular intervals
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Not applicable Interventional

HEalth Advocate for Liver Transplant - Pilot

NCT05700799
View directory record Official record
Conditions
Liver Transplant; Complications
Interventions
Health Advocate
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Active, not recruiting Phase 2 Interventional

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

NCT03420482
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Fecal Microbiota Transplant (FMT) oral capsules, Placebo oral capsule
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

NCT03781726
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
glecaprevir/pibrentasvir treatment
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue

NCT07102550
View directory record Official record
Conditions
Liver Transplant
Interventions
MiMedx AmnioFix
Biological
Lead sponsor
Jaekeun Kim
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Targeting Trimethylamine N-Oxide for Cardiovascular Health In Liver Transplant Recipients

NCT06043531
View directory record Official record
Conditions
Liver Transplant
Interventions
Experimental: EVOO
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

ATHN 11: Liver Transplantation Outcomes Study

NCT04055051
View directory record Official record
Conditions
Hemophilia A and B, Liver Transplantation
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients

NCT00497796
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
maribavir, ganciclovir
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 20, 2026, 5:30 AM EDT
Withdrawn Phase 1 Interventional

Hepatocyte Transplantation for Acute Decompensated Liver Failure

NCT01345565
View directory record Official record
Conditions
Liver Failure Acute
Interventions
human hepatocytes
Drug
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 20, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Pentoxifylline Therapy in Biliary Atresia

NCT01774487
View directory record Official record
Conditions
Biliary Atresia
Interventions
Pentoxifylline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 180 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

NCT00080236
View directory record Official record
Conditions
Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant

NCT02182687
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Not listed Early Phase 1 Interventional

Body Composition Changes After TIPS and Associated Clinical Outcomes

NCT05420753
View directory record Official record
Conditions
Cirrhosis, Liver, Sarcopenia
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

Impact of Age and BMI on Liver Transplant Outcomes

NCT04853641
View directory record Official record
Conditions
Liver Transplant; Complications, Perioperative/Postoperative Complications
Interventions
Cadaveric, Living Donor
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer

NCT00002515
View directory record Official record
Conditions
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Study of Resistance Strengthening Versus Ambulation Post-Liver Transplant

NCT01216722
View directory record Official record
Conditions
Liver Transplantation, Resistance Training, Activities of Daily Living
Interventions
Resistance Strengthening Exercise Program
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Oct 20, 2026, 5:30 AM EDT
Withdrawn Phase 4 Interventional

Minocycline Administration During Human Liver Transplantation

NCT02712775
View directory record Official record
Conditions
Liver Disease
Interventions
Minocycline (yes/no), Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 20, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation

NCT03193151
View directory record Official record
Conditions
Liver Dysfunction
Interventions
liver biopsy
Procedure
Lead sponsor
University of Alberta
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

NCT00644761
View directory record Official record
Conditions
Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Oct 20, 2026, 5:30 AM EDT
Completed No phase listed Observational

Assessing Outcome After H-graft Shunt Placement

NCT00519610
View directory record Official record
Conditions
Portal Hypertension
Interventions
Chart Review
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 20, 2026, 5:30 AM EDT
Not yet recruiting Phase 2 Interventional

Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)

NCT07862439
View directory record Official record
Conditions
Liver Diseases
Interventions
miRNA Biomarker-Guided Immunosuppression Minimization, Conventional Biochemical Monitoring-Guided Immunosuppression Minimization
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 5:30 AM EDT